STELARA (also known as Ustekinumab)
Stelara is an antibody that targets Interleukin 12 and 23, which are both important chemical messengers that activate T-cells. Stelara is designed to reduce inflammatory processes.
- Moderate-to-severe plaque psoriasis
- Active psoriatic arthritis
- Active, moderate-to-severe Crohn’s Disease who either failed or were intolerant to corticosteroids or failed or were intolerant to TNF blockers.
Patients with active infection should not be started on Stelara.
For patients with plaque psoriasis and psoriatic arthritis, Stelara can be administered as a subcutaneous injection at week 0, 4, and every 12 weeks thereafter. For patients with Crohn’s Disease, Stelara is typically administered and initiated as a single intravenous infusion dose; for maintenance, Stelara can be administered as a subcutaneous injection every 8 weeks thereafter.